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Abstract
Transplantation remains one of the most discussed 
surgical specialties within the media, from both a scientific and
ethical point of view. In a lifetime transplantation has moved from
a speculative experiment to a relatively commonplace lifesaving
set of procedures.  Within medicine, transplantation offers 
interaction between some of the sickest patients and the crafts 
of surgery,clinical immunology, and various medical specialities,
as well as being the subject of huge quantities of clinical and basic
scientific research. The many high profile advances in 
transplantation in recent years have been made possible by 
some very significant developments in the armamentarium 
of immunosuppressive drugs available for combating the rejection
process.  In this article, we will briefly discuss the rejection
process and the drugs which are used to counter it.
The Rejection Process.
Rejection of solid organ transplants revolves around the CD4+ T
lymphocyte, the helper T cell. This cell is activated by the presen-
tation to it of fragments of alloantigens by antigen-presenting 
cells (APCs) on their MHC class II molecules.1,2 This interaction
of the T cell’s receptor with the MHC class II / antigen complex
leads to internal signalling within the T-cell, which then increases
the production of the cytokine, interleukin 2 (IL-2)(B). IL-2 
is responsible for on-going activation of T-cells. This activation
leads to the effector arm of the immune response being recruited
to perform the task of destroying the transplanted graft. 
The effectors include cytotoxic T lymphocytes, which act to kill
the graft directly, antibodies produced by B-lymphocytes, 
or antigen non-specific macrophages, which cause a local ‘delayed
type hypersensitivity’3 Since the helper T cell is the key 
to the generation of such immune responses all current 
immunosuppressive drugs have a role in preventing T cell 
activation, in addition to any other roles they may play.
Methods of Preventing Transplant Rejection.
Aside from the miraculous but apocryphal (St Cosmos and 
St Damian’s leg transplant), and twin-to-twin transplants, 
transplant survival generally depends upon a cocktail of various
drugs. Immunosuppression is always a balance between 
preventing rejection of a given graft and leaving the patient 
vulnerable to overwhelming infection, or other adverse effects of
the therapy, such as end organ toxicity or malignancy.4, 5, 6 
When organ transplantation first began, the immunosuppression
used consisted of two drugs used in combination, azathioprine and
corticosteroids . Up to the early 1980’s, this was really the only
available prophylaxis against the rejection process, and it was not
unsuccessful, many  units still having long-standing patients in
their care on this regimen. The introduction of the drug ciclosporin
at this time markedly improved renal allograft survival.7 At the
same time antibody therapy, with either polyclonal or monoclonal 
anti-lymphocyte antibodies was introduced.8 However, since 1995
several news drugs have been introduced, including Tacrolimus,
mycophenolate mofetil (MMF), sirolimus, and two new 
monoclonal antibodies specific for the interleukin-2 receptor.9
More recently the aim of inducing transplantation tolerance 
has crept in to the vocabulary of the transplant physician. 
Rather than simply blocking activation, it aims to manipulate the
immune system in such a way as to enable the host immune 
system to tolerate a transplant, or more specifically be 
unresponsive to the antigens from the transplant, and thus greatly
reduce the level, if any, of drugs needed to prevent rejection.10
It implies that only the T-cells and B-cells responsible for graft
recognition would be immobilised or eliminated, leaving the rest
of the T- and B- cell populations available to participate in their
normal physiological role, thus reducing vulnerability 
to opportunistic infection, as well as reducing or preventing the
adverse effects of immunosuppresents. This area of transplant
immunology is the subject of much current interest and research.
Current cellular experimental approaches include introducing
donor cells into the circulation of the recipient, thus inducing
chimerism11
From a pharmacological point of view, a number of approaches
have been considered, but it is important to realise that generating
tolerance is more than simply blocking the recognition of antigen
specific responses, but rather is an active process. As described
above, antigen recognition by T-cells leads to generation of
intracellular messages. These messages are often referred to as
“signal one”. However, when a T-cell interacts with an antigen
presenting cell (APC), several non-antigen-specific interactions
also occur, leading to a second signal “signal two”. The most
important of these are between CD80 and CD86 on the APC and
CD28 on the T-cell, and also CD40 on the APC and CD40L on
the T cell. 
A number of experimental agents (CTLA4 Ig, anti-B7 antibodies
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and anti-CD40L antibodies) have been investigated to prevent
‘signal two’ from being generated since, if signal one is delivered
in the absence of signal two then antigen specific tolerance is
induced.11, 12, 13 There is much ongoing interest in this area. A further
method of inducing tolerance is to encourage deletion of 
graft-specific T-cells. Activated T-cells are susceptible to 
activation-induced cell death (AICD). The final drug described
below, rapamycin, promotes the susceptibility of  activated T-cells
to this apoptotic process, and this attractive method of inducing
tolerance is also under intense scrutiny.14
Immunosuppresive Drugs
Antimetabolites
Azathioprine inhibits purine metabolism, by competitively 
antagonising an enzyme  central to purine synthesis.15 More
recently, we have had access to the drug MMF, which is an ester
prodrug with higher bioavailability than its active agent, 
mycophenolic acid (MPA).16 This drug acts in a far more targeted
way than azathioprine, acting on the enzyme inosine 
monophosphate (IMP) dehydrogenase, which converts IMP to a
precursor of guanine. This pathway is important in nucleotide 
synthesis in lymphocytes, but less so in other cells Furthermore
MPA is almost five times more potent in inhibiting the isotype of
IMP dehydrogenase present in activated compared to resting 
lymphocytes. Studies have shown that MMF decreases the 
frequency and severity of rejection compared to azathioprine.16
So far this difference has not been shown to improve graft 
survival, though it is hard to perform a suitably powered study to
detect this difference.17 However MMF’s effects may in the long
term be shown to improve renal allograft survival.18
Corticosteroids
Prednisolone and methylprednisolone are both still used in 
transplantation. They function by reducing gene activation, 
which occurs if the signal induced by engagement of the T-cell
receptor is successfully transduced to the nucleus.3 Expression of
genes that lead to the production of pro-inflammatory cytokines 
re among those inhibited by steroids, thus reducing T cell 
activation. How exactly steroids do this is only now becoming
clearer and is thought to be based mainly on interference 
with transcription factors, such as activator protein-1 (AP-1) 
and nuclear factor kappa B (NF-kappa B).3
The reduction of lymphocyte proliferation seen with the use of
these drugs is likely to be due to the reduction of cytokine 
production. Reduced expression of genes coding for adhesion
molecules leads to reduced leukocyte migration.19, 20 However,
their long term use has a well known plethora of adverse effects
(such as Cushing’s syndrome, osteoporosis, cataracts, peptic
ulcers, glucose intolerance, hypercholesterolemia, skin fragility,
and adrenal suppression) and many units thus aim relatively
rapidly to wean patients off corticosteroids. 
Calcineurin Inhibitors.
Calcineurin is a phosphatase which is activated if an antigen 
is recognised by a T-cell. It allows a promoter called “nuclear
factor of activated T cells” (NFAT) to enter the nucleus and 
promote the transcription of several cytokine genes, including
IL-2. By inhibiting this enzyme, ciclosporin and, more recently,
tacrolimus prevent this from occurring.10, 21 Thus the message 
that the T-cell receptor has recognised antigen does not 
reach the nucleus. 
Both drugs are in use, but evidence suggests that tacrolimus 
is associated with a lower incidence of acute rejection.22, 23
They have differing adverse effects, but both require monitoring
of their blood levels, due to their narrow therapeutic windows23
Inteleukin-2 receptor blockade
The action of IL-2 can be blocked at its receptor (CD25), 
which has lead to the development of two anti-CD25 antibodies,
basiliximab and daclizumab, produced by genetic engineering.
They were developed from mouse monoclonal antibodies specific
for the chain of the human interleukin-2 receptor, but importantly
only the variable domains of the light and heavy chains of 
basiliximab, and the three complementarity-determining regions
of each variable domain in daclizumab are of mouse origin.24, 25
This means that both these antibodies are much less likely to 
be seen as a foreign protein and thus be removed by the patient’s
immune system. Trials have shown that these drugs both reduce
acute rejection.26
mTOR Inhibitors 
Successful interaction of IL-2 with its receptor leads to the 
generation of a signal within the cell, starting the cell cycle and
leading to proliferation.27 Increasing evidence suggests that
mTOR, a regulatory kinase, acts as a central controller in this,
sensing cellular environment (mitogenic stimulation) and 
regulating translation initiation through the eukaryotic initiation
factor 4E, and ribosomal p70 S6 kinase pathways, thus allowing
the cell to enter the cell cycle9, 27 Rapamycin (now called
sirolimus) inhibits this process. It is not yet clear how best to use
this agent. We do know that adding this drug to the regimen of
ciclosporin and prednisolone decreases  acute rejection28, and it
can also be substituted for ciclosporin29, avoiding the 
nephrotoxicity encountered with this drug. 
Face, Hand and Other Composite 
Tissue (CT) Transplantation
The arguments against performing a face transplant are similar to
those applied to hand transplantation. The performing of a hand
transplant was not uncontroversial6,30,31 many arguing that the risk
of long term adverse effects of immunosuppression did not 
outweigh the benefits of gaining a hand. Indeed the first recipient
of such a transplant was unable to tolerate the side effects of his
drug regime and thus lost his transplant.31 However, as described
above, over 20 hand transplants have been performed to date, 
and so far only two have been lost. The longest surviving hand
transplant has been in situ for more than five years, with reports in
the media of excellent function (CNN website, 28th February
2004). This has become possible because of the developments
both in understanding the rejection process and also the 
continuing work in developing new drugs that target this process,
as well as improved microsurgical technique.30
The regime used for hand transplants (tacrolimus/MMF/
prednisolone) works by blocking the signals that generate an
immune response in three different areas as described above. 
The fact that successful hand transplants have occurred 
demonstrates well the power of modern immunosuppressive
drugs. The immunogenicity of composite tissues, particularly skin
should not be underestimated, due to the presence within it of a
large number of cells of the immune system, including high 
numbers of dendritic cells, which easily trigger an immune
response.33 Furthermore it can be argued that there is a much more
limited functional reserve in composite tissues, so any rejection
episode may have more obvious effects than in solid organ 
transplants30
High levels of immunosuppression are going to have long term
adverse effects, as described above, and thus the development of
mechanisms inducing tolerance would greatly benefit face 
transplantation. Work in small animal models has shown that it is
possible to generate tolerance, though so far this has not been 
reproduced in larger animal models. Obviously the ability 
to induce tolerance to transplanted composite tissues would help
overcome the scepticism that many in the transplant community
have towards composite tissue transplantation.  The final point to
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be made is that the long term survival of composite tissue grafts
will be dependant on the avoidance of chronic rejection.30
Only time and experience will tell us what is in store for us here.
Conclusion
There is much work still ongoing in the development of strategies
to counter transplant rejection in all areas of transplantation, and
possibly develop tolerance. There are still many areas in which
things can be improved. For example, the commonest cause for
loss of a renal transplant is death of the patient with a functioning
graft, at an age in advance of what would be predicted for a
healthy, age-matched individual32  Whilst part of this pathology
will reflect the impact of past renal disease and dialysis, 
the adverse effects of immunosuppressive drugs will also have
played a role. Reducing this pathology is a major focus within 
the transplant community today, and would greatly benefit 
recipients of all types of transplant.
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The mainstay of treatment for many diseases affecting the face and
mouth is still surgery.  However, like so many medical problems,
there are different techniques and nuances for treating these 
diseases and injuries.  A lot of these subtleties of approach are
steeped in history and have stood the test of time.  They are passed
from one generation of surgeons to the next with minor 
modifications that naturally follow on from our method of 
training, which is essentially an apprenticeship to surgical masters.  
These methods do achieve success in most cases otherwise they
would have been discarded long ago, but comparisons between
different techniques for the same condition in prospective 
randomised studies are sparse for many surgical groups. 
The commonest form of evidence provided to support particular
treatment protocols is the case series (level III).  It is still uncom-
mon to find level II (prospective randomised studies) or level I
(metanalyses). The consequence of this failure to compare 
different techniques is difficulty in adducing evidence which
defines best treatment for these conditions, especially where it
relates to more subtle parameters such aspost-operative pain 
experience, quality of life and complications.
The general public’s perception is that there are standard 
operations for all conditions, particularly the common ones such
as hernia repair, varicose vein elimination or wisdom tooth
removal. They believe that all surgeons carry out these operations
in the same manner.  They are shocked when they realise that 
surgeons may perform these operations very differently.
There are several reasons why surgical techniques are not 
compared in a prospective randomised fashion.  Some of these
relate to practical problems whilst others are more philosophical.
Firstly, prospective randomised studies demand scrupulous data
